The Bayer CEO Bill Anderson faces a challenge at the annual general meeting on Friday, as he must deal with massive shareholder criticism. In particular, the company's problems such as the waves of lawsuits for glyphosate and PCBs in the USA, high debt, and challenges in the pharmaceutical pipeline will be addressed.

The Critics, Including Ingo Speich of Deka and Janne Werning of Union Investment, Demand Solutions for These Problems from Anderson. They Emphasize That Shareholders Have Already Made Their Contribution to Bayer's Financial Stability by Almost Completely Foregoing Dividends and Now Expect Answers.

The financial burden from billion-dollar legal disputes in the USA, particularly in connection with glyphosate and PCBs, has put Bayer under pressure. Despite revenue growth in the past quarter, market expectations and the company's future prospects are in question.

Anderson, however, attempts to spread optimism by announcing a new leadership model intended to accelerate Bayer and reduce costs. Nevertheless, many investors remain dissatisfied and demand a quicker resolution to legal issues as well as a more convincing strategy from Anderson.

Some investors had hoped for a split or sale of company divisions, which, however, Anderson has so far rejected. Instead, the company is considering legal and political measures to settle the legal disputes and improve the situation.

Despite current efforts, Bayer's future remains uncertain, and many investors hesitate to invest in the company as long as the legal disputes continue. Bayer's stock exhibits a volatile reaction during the annual general meeting, as the company continues to struggle to regain investor confidence.